Clinical studies about avelumab, atezolizumab and durvalumab
| Indication | Study | ||||||||
| Reference & clinical trial | n. | Objective response rate (ORR) % (95%CI) | Treatment-related (TR)all grades adverse events (%) | TR grade 3–4 adverse events (%) | Survival vs. control therapy survival | Control therapy & ORR %
(95% CI) | Control therapy TR all grades adverse events (%) | Control therapy TR grade 3–4 adverse events (%) | |
| Avelumab | |||||||||
| Metastatic merkel cell carcinoma | Kaufman et al.58 (NCT02155647) | 88 | 31.8
(21.9–43.1) | 70 | 5 | 40% (6-month progression-free survival rate) | |||
| Locally advanced or metastatic urothelial carcinoma | Patel et al.59 (NCT01772004) | 161 | 17
(11–24) | 58 | 8 (one case has grade 5 pneumonitis) | 6.5 months (median overall survival) | |||
| Atezolizumab | |||||||||
| Locally advanced or metastatic urothelial carcinoma | Rosenberg
et al.60 (NCT02108652) | 310 | 15
(11–19) | 69 | 16 | 7.9 months (median overall survival) | |||
| Locally advanced or metastatic urothelial carcinoma | Rittmeyer
et al.36 (NCT02008227) | 425 | 14 | 64 | 15 | 13.8 months vs. 9.6 months (overall survival) | Docetaxel 16 (n=425) | 86 | 42 |
| Durvalumab | |||||||||
| Locally advanced or metastatic urothelial carcinoma | Powles et al.37 (NCT01693562) | 191 | 17.8
(12.7–24.0) | 60.7 | 6.8 | 1.5 months (median progression-free survival) | |||